文献速递慢性肾脏病肾小球疾病

中医药在慢性肾脏病中的应用:误区、事实与证据

Traditional Chinese medicine in CKD: myths, facts, and evidence.
PubMed 文献 · Nephrol Dial Transplant · 2026-10-26

本综述以循证医学框架审视中医药在慢性肾脏病(CKD)中的误区与事实。随机证据有限,但SCHEMATIC试验显示地黄-6类中药辅助治疗与2型糖尿病合并CKD患者48周内eGFR下降较慢相关;一项多中心随机试验显示肾气丸颗粒治疗膜性肾病可降低蛋白尿,缓解结局与常规免疫抑制治疗相当。这些发现支持假设而非定论,安全性不应因天然来源或历史使用而推断。

要点

  • 随机证据有限,SCHEMATIC试验和肾气丸颗粒试验提供假设性信号。
  • 两项试验均未确立肾脏衰竭、心血管事件或死亡率的降低。
  • 安全性不应从天然来源或历史使用推断,需评估产品质量与相互作用。

核心结论

  • 中医药在CKD中的作用仍有争议,现有随机证据有限且为假设支持性而非确定性。
  • 中药的未来角色应由可重复质量、临床获益和可接受的风险获益比决定。

研究设计与样本

  • 综述,通过循证医学框架批判性审视中医药在CKD中的误区与事实,检索范围未报告。

主要发现

  • SCHEMATIC试验发现地黄-6类中药辅助治疗与2型糖尿病合并CKD患者48周内eGFR下降较慢相关。
  • 肾气丸颗粒多中心随机试验在膜性肾病中降低蛋白尿,缓解结局与常规免疫抑制治疗相当。
  • 两项试验均未确立肾脏衰竭、心血管事件或死亡率的降低,且缺乏独立验证。

关键数值与推荐

  • SCHEMATIC试验:48周内eGFR下降较慢(数值未报告)。
  • 肾气丸颗粒试验:蛋白尿降低,缓解结局与常规免疫抑制治疗相当(数值未报告)。

临床怎么用

  • 临床应基于产品特异性证据评估中药,而非泛化推广或否定。
  • 使用中药时需关注产品质量、植物鉴定、药代动力学、毒理、药物相互作用和药物警戒。

局限性

  • 随机证据有限,两项试验未评估硬终点如肾脏衰竭、心血管事件或死亡率。
  • 缺乏独立确认,产品特异性和标准化生产不足。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Traditional Chinese medicine (TCM) is increasingly used among patients with chronic kidney disease (CKD), particularly in regions where healthcare resources, accessibility and cultural acceptance influence treatment choices. However, its role in the treatment of CKD remains controversial, with conflicting perceptions ranging from therapeutic promise to concerns regarding unproven efficacy and potential toxicity. In this review, we critically examine some myths and facts surrounding TCM use in CKD through the framework of evidence-based medicine. Randomized evidence remains limited, but a few trials have reported clinically relevant signals. In patients with type 2 diabetes and CKD, the multicenter SCHEMATIC trial found that add-on Rehmannia-6-based Chinese medicine was associated with a slower decline in eGFR over 48 weeks. In membranous nephropathy, an earlier multicenter randomized trial of Shenqi particle reported reductions in proteinuria and remission outcomes comparable with conventional immunosuppressive therapy. These findings are hypothesis-supporting rather than definitive: neither trial established a reduction in kidney failure, cardiovascular events or mortality, and independent confirmation is lacking. Importantly, safety should not be inferred from natural origin or historical use. Product quality, botanical authentication, pharmacokinetics, toxicological evaluation, herb-drug interactions and pharmacovigilance are essential components of responsible clinical evaluation. Future research should move beyond the broad question of whether 'TCM works' and instead focus on product-specific assessment using rigorous trial methodology, standardized manufacturing, precision CKD phenotyping and internationally applicable outcome measures. Chinese herbal medicines should neither be dismissed solely because they are traditional nor accepted solely because they are natural. Their future role in CKD care should be determined by the same principles applied to any therapeutic intervention: reproducible quality, demonstrated clinical benefit and an acceptable benefit-risk profile.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Chen Q, Liang Y, Bai J, et al. Traditional Chinese medicine in CKD: myths, facts, and evidence. Nephrol Dial Transplant. 2026. PMID: 42931903. doi:10.1093/ndt/gfag247

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。